CanBas Co

CanBas Co OpEx/Revenue

The Operating Expenses to Revenue Ratio of CanBas Co (4575.T) as of Oct 22, 2026 is 1,248.63 %. In the previous year, Operating Expenses to Revenue Ratio was 602.70 % — a change of 107.17% (higher).

OpEx/Revenue

1,248.63 %

YoY

107.17%

Last updated:

Operating Expenses to Revenue Ratio of CanBas Co is 2022 1,248.63 % . Operating Expenses to Revenue Ratio of CanBas Co was 2021 602.70 % . It decreases by 107.17% higher compared to the previous year.

The CanBas Co OpEx/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OpEx/Revenue
Date
OpEx/Revenue
Jan 1, 2015
565.14 JPY
Jan 1, 2016
479.23 JPY
Jan 1, 2017
324.00 JPY
Jan 1, 2018
590.41 JPY
Jan 1, 2019
561.34 JPY
Jan 1, 2020
615.27 JPY
Jan 1, 2021
602.70 JPY
Jan 1, 2022
1,248.63 JPY
The CanBas Co OpEx/Revenue history
YEAROpEx/RevenueYoY
1,248.63 %+107.17%
602.70 %-2.04%
615.27 %+9.61%
561.34 %-4.92%
590.41 %+82.23%
324.00 %-32.39%
479.23 %-15.20%
565.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Operating Expenses to Revenue Ratio of CanBas Co is 1,248.63 % in 2022.

Operating Expenses to Revenue Ratio of CanBas Co changed from 602.70 % to 1,248.63 %, representing a 107.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio CanBas Co since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CanBas Co

All Key Metrics — CanBas Co